Old Web
English
Sign In
Acemap
>
Paper
>
Mo1279 Durability of Benefit in IBS-D Patients Responding to a 2-Week Course of Rifaximin: Results From TARGET 3
Mo1279 Durability of Benefit in IBS-D Patients Responding to a 2-Week Course of Rifaximin: Results From TARGET 3
2015
Mark Pimentel
Lin Chang
Anthony Lembo
Andrew C. Barrett
Jing Yu
Enoch Bortey
Craig Paterson
William P. Forbes
Keywords:
Rifaximin
Physical therapy
Medicine
Durability
Internal medicine
General surgery
Diabetes mellitus
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI
[]